Saxol

Neuroprotecting

Patient's Future

Philippe Bordeau, CEO

Dec 2025

First Preventive Treatment for all Peripheral Neuropathies

'...the findings are truly impressive. I am convinced that Carba1 holds significant promise as an innovative solution'

Pr Ahmet Höke, PhD, MD, Johns Hopkins Medicine, Department of Neurology (MD)

i-Lab

FRANCE 2030

Saxol

Saxol
Neuroprotecting
Patient's Future

A French biotech startup at a pre-clinical stage developing the First preventive treatment applying to all peripheral neuropathies causes

Based on its proprietary & protected breakthrough therapy

Addressing a global Recognized Unmet Medical Need

For all patients suffering from a lack of protection of the nerve fibers

Team

Saxol
Neuroprotecting
Patient's Future

Founders & Executive Team

Philippe Bordeau, MSc
Saxol CEO
Founder of several Biotechs
Strategy, IP, Collaborations,
Financing skills including non dilutive multiple financing
20 M€ on 40 M€ for Alaxia

Laurence Lafanechère, PhD,
Saxol Scientific adviser
CNRS Director of Research
IAB deputy director
Carba1 Inventor
Member of Ruban rose Scientific Committee , +80 publications

Victor Juarez Perez, PhD, MBA
Saxol CSO/COO
Team Leader of several pharma complex programs (ALX-009, STR-324...).
Scientific and regulatory strategy, interactions with FDA/EMA.
+20 articles in peer-review journals

Lauriane Bosc, MSc
Saxol Preclinical Manager
Study engineer on several FUI projects
3y working on Saxol project

Paul Claudon, Ing, PhD
Saxol CMC support
Medicinal chemist managing drug manufacturing, analytics and quality aspects

Scientific & Medical advisory board

Ahmet Hoke, MD, PhD
Pr Neurology Johns Hopkins,
Head Neuromuscular Division
Editor in chief *Experimental Neurology*, Annals of Clinical and Translational Neurology
Author of 174 publications

Annie Claude Benichou, MD
Methodologist, Former QPPV and Medical Director of Stragen group
CMO of several drug dvpt program (OMA, STR-324,…)

Jesus Garcia-Foncillas MD PhD
Pr Oncology, Madrid University
Dr Cancer Institute
Dr Oncohealth Institute
Dr Oncology Dpt at FJD Univ. Hosp.
Dr Translational Oncology Research Institute FJD
Author of 220 publications and several books on cancer

Stanislas Quesada MD PhD
Oncologist,
Focused Patient QoL
ICM Montpellier
Inserm Researcher
Author of 60 publications

Saxol Planned Organigram



Recruitments according program progression

Context: Peripheral Neuropathy (PN)

Saxol
Neuroprotecting
Patient's Future

PN, a disorder affecting peripheral nerves
outside the brain and spinal cord

Nerve damage symptoms

- Sensitivity disorders
- Neuropathic Pain
- Muscles weakness
- Hearing loss
- Cognitive

PN Impact on daily life

- Loss of balance and increased risk of fall
- Motor impairment
- Reduced quality of life
- Depression, anxiety and insomnia



Problem: PN causes are not treated & multiple

Saxol
Neuroprotecting
Patient's Future

- **Drug adverse side effects**
  - Immunotherapies, Antibody Drug Conjugate (Emerging adverse event)
  - Chemotherapies (Chemotherapy-Induced Peripheral Neuropathy - CIPN)
    - 10 Million/y patients treated worldwide (15 M in 2040)
- **Neurodegenerative diseases**
  - Alzheimer, Parkinson, etc. - over 70 Million patients (WHO)
- **Metabolic**
  - >530 Million diabetes patients in 2021 (> 700 Millions by 2040)
  - Gangrene & amputation risks
- **Aging**
  - 7-12% of general non-diabetic population
  - Over 750 Million people worldwide >65yo
- **Trauma, Infections**

Millions of patients with no therapeutic options

No preventing/curing treatment available for nerve fibers

One common cellular origin

Saxol
Neuroprotecting
Patient's Future

NAD^+ ↘

NERVE FIBERS DAMAGE

Chemo Induced PN	Diabetes PN	Aging	Other PN (Infections,…)	Trauma
				



Nerve representation

Our solution: Carba1

Saxol
Neuroprotecting
Patient's Future

Carba1 NAMPT activator restores NAD^+ intracellular levels



Normal NAD^+ salvage pathway



In neuropathic conditions **NAD^+** production is **impaired**



Carba1 **rescues** NAD^+ production by **regulation of NAMPT**

NAD^+, nucleotide present in all living cells.
NAD^+, cofactor & substrate for a multitude of essential processes including energy production, DNA repair,…
NAMPT, key enzyme producing NAD^+

Breakthrough therapeutic approach

Results: Strong evidence of effectiveness detailed in Annex

Saxol proposal : *CarbaS*, new class of Drugs

Saxol
Neuroprotecting
Patient's Future

- **Carba1 - Lead and first product coming out pipeline**
- **Pipeline Patented & Free to Operate**
- **Breakthrough therapeutic approach**
  - New in class
  - New MoA - NAMPT activator: NAD^+ restauration ↗
  - Protecting nerve fibers
- **Derived from a Carbazole structure (MedChem)**
- **Other derivatives available**



New class of drugs: NAMPT activators

CIPN First indication to open

Saxol
Neuroprotecting
Patient's Future

CIPN indication, Fastest access to Phase IIA

In vitro efficacy

Regulatory

Pharmacology & toxicity

Phase IB/IIA
Chemotherapy-Induced Peripheral Neuropathy

Lead

Final validation

Diabetes PN

Aging PN

...

Carba1 structure

Way paved for potential additional indications



Nerve cell & organization

Chemotherapy-Induced Peripheral Neuropathy

Saxol
Neuroprotecting
Patient's Future

- **A very common cancer treatment adverse event**
  - Usual cause of treatment interruption or dose reduction
  - 70% of patients are affected after one month of treatment
  - 30% of patients remain affected 6 months after ending treatment
- **Chemotherapy use in cancer treatment : > 50%***
  - 10 Million patients treated ww each year by chemo - 15 Million patients in 2040
  - € 10+bn SAM in EU - 3.1 Million CIPN patients EU+US

  *Even by 2040 – IARC/WHO – Wilson B, The Lancet
- **No treatment preventing CIPN nor PN approved**



Nerve ending degeneration due to lack of energy generated in mitochondria leads to chronic CIPN

Unmet Medical Need

FDA/EMA Special Programs

Breakthrough therapy, PRIME

FDA

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Competitive landscape for CIPN

Saxol
Neuroprotecting
Patient's Future

> 60 Pain Killers

- ✘ Pain only
- ✘ Not addressing root cause
- ✘ Not preventing nor curing

Anti-epileptics

- ✘ CNS side-effect
- ✘ Risk of respiratory issues
- ✘ Poor efficacy

Anti-depressants

- ✘ Long timeframe for "efficacy"
- ✘ Cognitive impairment
- ✘ Poor efficacy

Palliative approaches

No Nerve Fibers Protection

✔

Preventing Therapies
CIPN early-stage dvpt

Saxol
Neuroprotecting
Patient's Future

SONNET BioTherapeutics

OSMOL

Regenacy Pharmaceuticals

Competitors in CIPN

Saxol
Neuroprotecting
Patient's Future

	Indications	Production costs	Development stage	Risks
Saxol	All PN CIPN 1st indication	Low	Preclinic	No IP risk Low tox risk
OSMOL	CIPN Only one indication to be considered (taxane only)	Low, Camcolit® repositioning	Phase I	High risk counterfeiting
~~SONNET BioTherapeutics~~ ALKEM	CIPN & Diabetes PN India	High, Biotherapy	Phase II	IL-6 can induce significant adverse effects

HDAX therapeutics not represented here. HDAX target HDAC6 and is at lead selection. Augustine is also targeting HDAC6 but for CMT indication

Effectiveness - Strong evidence available

Saxol
Neuroprotecting
Patient's Future

Carba1 *In vitro* Neuroprotection





Carba1 *In vitro* effects on neuropathies induced by Cisplatin



Effectiveness

Strong evidence available

Carba1 In vivo *evidence on Neuroprotection*



Nerve fibers in green





Fibers widely affected

Saxol at a glance

- **A young pre-clinical stage biotech piloted by a skilled team**
  - Strong, visionary & complementary team (Science, CMC, Reg, …)
  - Intl Scientific Medical Board Installed
- **Game Changer Assets**
  - Pipeline patented, NAMPT, NAD^+ restoration
  - Pipeline including neuroprotective and analgesic compounds
- **Unmet Medical Need (no product preventing PN)**
  - CIPN, a major Unmet Medical Need as first indication
  - DPN, as second indication
  - Aging PN, ALS, CMT,… further indications
- **Strong body of evidence already available**
- **Robust Roadmap incl. Health Agencies scientific advices**
- i-Lab **award** FRANCE 2030

Carba1 1st product preventing PN

CarbaS

Breakthrough therapies

Growth potential ↗

High demand

SAM

> € 10+bn
(on CIPN indication only)

CIPN Roadmap (DPN Launch included)



Timeline

CIPN Phase IIB
Compassionate
…

Diabetes
Aging
…

2030 Licensing out
CIPN Program

CIPN
Phase IB/IIA

Funding 3 – S1 2028 — **€ 10m -… CIPN**

Milestone 2 : CTA
Funding 2 – S2 2026 — **€ 3.0m CIPN (€ 2.0m DPN)**

Milestone 1 : CMC dossier
+ Ready Preclinic Tox
Funding 1 – S2 2025 — **€ 2.0m**

Work Program detailed

Highlights

- **2025-2026**
  - CMC, Non-Clinic, Regulatory. All activities launched
- **2027**
  - Regulatory Toxicology Program completion (subacute tox)
- **2028**
  - CTA request, CIPN Clinical Study phaseIB/IIA start
- **2029**
  - CIPN Clinical Study phaseIB/IIA
- **2030**
  - CIPN Program Licensing Out

CMC : Chemical Manufacturing & Control
DS : Drug substance, active ingredient
DP : Drug product, galenic formulation
IMPD : Investigational Medicinal Product Dossier
PoC : Proof of Concept

CIPN : Chemo-Induced Peripheral Neuropathies
DPN : Diabetes Peripheral Neuropathies
CTA : Clinical Trial application
IB : Investigator's Brochure
PoI : Proof of Interest

Round 2– Use of Funds

- **Regulatory Preclinical Tox**
  - Genotoxicy
  - Safety Pharmacology
  - Acute and sub acute (3mo)
- **CMC**
  - GMP DS/DP Manufacturing
  - IMPD preparation
- **Clinical Trial Preparation**
  - Design
    - Umbrella type protocol
    - Tolerability and efficacy of Carba1/Taxane vs Taxane
    - **Biomarkers and biological testing** as main readouts for efficacy
  - PI and sites selection
- **Regulatory**
  - Pre-IND and scientific advices (FDA, MHRA, EMA/EU National Authorities)
  - IMPD, IB and CTA preparation
- **General**
  - Staff reinforcement (Clin, Qual)
  - IP additional protections

Saxol
Neuroprotecting
Patient's Future



Saxol SAS - Corporate Information

- **Corporate**
  - Incorporated Nov 2024
  - SAS Company, P. Bordeau President & CEO
  - Board & SMB in place
- **ESG**
  - **A 21st century company socially, economically and ecologically** accountable
  - Manifesto in place
- **Pipeline**
  - CarbaS,… as neuroprotective compounds
  - Non-Opioid Pain Killer available for partnering &/or to improve for higher licensing value
- **IP situation**
  - Saxol owns exclusive CNRS/Linksium Patents license
    - 2 patents, 2019 & 2024. FtO
  - Additional patent(s) to be requested during drug development
- **Fundraising**
  - Looking for 3 M€ in Round 2 for CarbaS

Shareholders
(Round 1 completed)



Pipeline

Saxol develops several programs

	Entity	Discovery	Preclinical	PhaseI	PhaseIIA
Peripheral Neuropathy (Nerve fibers protection)	Small Molecule (CarbaS)	SAX-101 in CIPN SAX-102 in DPN			
Pain (Analgesic)	Peptide	SAX-201* in Neuropathic Pain &/or Cancer Pain (Based on STR-324 program)			
		STR-324 in Post-Op pain			

*Specific slidedeck available

Saxol in the News

UP Re.Search, South Africa

Saxol, Startup of the year

Click on me youtube video

The Conversation

RTS, Switzerland

Le Figaro, Paper edition Nov 10, 2025

RTBF Belgium

Polytechnique alumni magazine



Supporting Publications

Bosc L, Pero ME, Balayssac D, Jacquemot D, Allard J, Suzanne P, Vollaire J, Cottet C, Michallet S, Villaret J, Torch S, Marais S, Elena-Herrmann B , Schlattner U, Mercier A, Josserand V, Thibert C, Dallemagne P, Bartolini F, Lafanechère L, Preventing neuropathy and improving anti-cancer chemotherapy with a carbazole-based compound available here. Sci Adv 2025 Oct 31;11(44):eadw6328

Lafanechère L, The microtubule cytoskeleton: An old validated target for novel therapeutic drugs. *Front Pharmacol. 2022 Sep 15;13:969183*.

Hoke A, Cerri F, Fisgin A, Riva N, Quattrini A, Normal structure and pathological features in peripheral neuropathies, *J Peripher Nerv Syst 2021 Nov:26 Suppl 2:S11-S20.*

Laisne MC, Michallet S, Lafanechère L, Characterization of Microtubule Destabilizing Drugs: A Quantitative Cell-Based Assay That Bridges the Gap between Tubulin Based- and Cytotoxicity Assays, *Cancer 2021 Oct 18;13(20):5226.*

Peronne L et al, Two Antagonistic Microtubule Targeting Drugs Act Synergistically to Kill Cancer Cells. *Cancers. 2020 Aug; 12(8): 2196*

Peronne L, Caractérisation d'un nouveau compose pharmacologique qui potentialise la réponse des cellules au paclitaxel, *Biologie du développement – Oncogenèse Thesis, 2019*

Issaa S, Prandina A, Bedel N, Rongved P , Yous S, Le Borgne M, Zouhair B Carbazole scaffolds in cancer therapy: a review from 2012 to 2018. *Enzyme inhibition and medicinal chemistry 2019, vol. 34, no. 1, 1321–1346*

Wilson B, Jacob S, Yap M, Ferlay J, Bray F, Barton M Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study *Lancet Oncol 2019: 20: 769–80*



Neuron representation (including axon)

Saxol

Neuroprotecting
Patient's Future

Follow us

www.saxol.eu

contact@saxol.eu

Saxol SAS,
31 Rue Gustave Eiffel,
F-38000 Grenoble

i-Lab Award

Supported by

FRANCE 2030 Linksium cnrs bpifrance

Saxol

Neuroprotecting

Patient's Future

Scientific Additional informations

Neurology

Carba1 In vitro effects on neuropathies induced by Cisplatin

Number of neurons

NF (+) Cells in a primary culture of sensory neurons and Schwann cells Injured with Cisplatin



Length of neuronal network

Length of the neurite network in a primary culture of sensory neurons and Schwann cells injured with Cisplatin



Axon myelination

Peripheral myelination in a primary culture of sensory neurons and Schwann cells injured with Cisplatin



Control | *Carba1* 1 µM | *Carba1* 5 µM | *Carba1* 10 µM | P7C3 5 µM

Neurology

Carba1 In vitro Neuroprotection - Paclitaxel



Neurology

Carba1 In vitro Neuroprotection – PTX, Cisplatin & Bortezomib









Neurology
Carba1, In vivo evidence on Neuroprotection

Saxol
Neuroprotecting
Patient's Future





Nerve fibers in green





Fibers widely affected

Carba1 protects nerve fibers

Oncology
Carba1 does not stimulate tumor growth

› Carba1, Paclitaxel (PTX) and combined effects on tumoral growth in mice

A





HeLa cells were injected into the flank of mice. When the tumors have reached a sufficient size, mice were treated (dashed line) with **Carba1** or **PTX** only or with a **combination of the two**

B



NAMPT activation is generally thought to stimulate tumor growth. Our findings demonstrate that **Carba**1 does not.

***Carba1* is not protumoral**
***Carba1* does not compromise PTX antitumoral efficacy**

Oncology
Carba1, Also a Taxane booster

Compound dose required to reach IC_{50} (HeLa cells)



Chemotherapy alone

Chemotherapy + *Carba1*

IC_{50} divided by 2 at least

Carba1 – Dual Interest
for Peripheral Neuropathies Induced by Taxane



Protecting neurons & Reducing Taxane dose

2 ways to reduce CIPN